SCHEMBL23833713

SCHEMBL23833713

NCCCCCCOc1ccc(NC(=O)c2c[nH]cn2)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.47
MEN1 O00255 9/20 0.47
LMNA P02545 7/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
ALDH1A1 P00352 4/20 0.47
ALOX12 P18054 3/20 0.47
GAA P10253 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
MAPT P10636 11/20 0.44
HTT P42858 4/20 0.44
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
IDH1 O75874 3/20 0.40
HPGD P15428 1/20 0.36
TP53 P04637 1/20 0.36
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833769 0.93 KMT2A (0.46) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL23846358 0.88 MAPT (0.43) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25759529 0.87 MAPT (0.48) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL23846321 0.85 KMT2A (0.51) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL23833757 0.78 SIRT2 (0.39) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL23846419 0.77 KMT2A (0.52) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25755498 0.67 KMT2A (0.62) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL23846462 0.66 MAPT (0.49) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25755512 0.66 KMT2A (0.62) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL23846580 0.66 KMT2A (0.68) KMT2AMEN1LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
EP-4121029-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 KMT2A 4864/4885MEN1 3902/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.